Lineage Cell Therapeutics to Report Fourth Quarter & Full Year 2020 Financial Results & Provide Bus. Update on March 11, 2021
March 01 2021 - 8:00AM
Business Wire
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX),
a clinical-stage biotechnology company developing allogeneic cell
therapies for unmet medical needs, today announced that it will
report its fourth quarter and full year 2020 financial and
operating results on Thursday, March 11, 2021, following the close
of the U.S. financial markets. Lineage management will also host a
conference call and webcast on Thursday, March 11, 2021, at 4:30
p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth
quarter and full year 2020 financial and operating results and to
provide a business update.
Interested parties may access the conference call by dialing
(866) 888-8633 from the U.S. and Canada and (636) 812-6629 from
elsewhere outside the U.S. and Canada and should request the
“Lineage Cell Therapeutics Call”. A live webcast of the conference
call will be available online in the Investors section of Lineage’s
website. A replay of the webcast will be available on Lineage’s
website for 30 days and a telephone replay will be available
through March 19, 2021, by dialing (855) 859-2056 from the U.S. and
Canada and (404) 537-3406 from elsewhere outside the U.S. and
Canada and entering conference ID number 4176568.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology
company developing novel cell therapies for unmet medical needs.
Lineage’s programs are based on its robust proprietary cell-based
therapy platform and associated in-house development and
manufacturing capabilities. With this platform Lineage develops and
manufactures specialized, terminally differentiated human cells
from its pluripotent and progenitor cell starting materials. These
differentiated cells are developed to either replace or support
cells that are dysfunctional or absent due to degenerative disease
or traumatic injury or administered as a means of helping the body
mount an effective immune response to cancer. Lineage’s clinical
programs are in markets with billion dollar opportunities and
include three allogeneic (“off-the-shelf”) product candidates: (i)
OpRegen®, a retinal pigment epithelium transplant therapy in Phase
1/2a development for the treatment of dry age-related macular
degeneration, a leading cause of blindness in the developed world;
(ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a
development for the treatment of acute spinal cord injuries; and
(iii) VAC, an allogeneic dendritic cell therapy platform for
immuno-oncology and infectious disease, currently in clinical
development for the treatment of non-small cell lung cancer. For
more information, please visit www.lineagecell.com or follow the
Company on Twitter @LineageCell.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210301005116/en/
Lineage Cell Therapeutics, Inc. IR Ioana C. Hone
(ir@lineagecell.com) (442) 287-8963
Solebury Trout IR Gitanjali Jain Ogawa
(Gogawa@troutgroup.com) (646) 378-2949
Russo Partners – Media Relations Nic Johnson or David
Schull Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com (212) 845-4242
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Sep 2023 to Sep 2024